Cancer medication combinations pose unique bioequivalence challenges for generics. Small changes in drug absorption can affect safety and efficacy. Learn how regulators, hospitals, and manufacturers are adapting to ensure affordable cancer care without compromising outcomes.
The FDA's Orange Book is the official database of approved drug products with therapeutic equivalence ratings, enabling generic drug competition and saving billions in healthcare costs through transparent patent and exclusivity data.
© 2026. All rights reserved.